Clinical Trials Logo
  1. Home
  2. Oral Lichen Planus
  3. NCT04336488
  4. Details
NCT04336488 Clinical Trial

Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

Oral Lichen Planus Clinical Trial

Official title:
Effectiveness of Matrix Metalloproteinase Neutralizing Agent in Treatment of Oral Lichen Planus: A Pilot Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT04336488
Other study ID # MMPs in lichen
Secondary ID
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date January 1, 2020
Est. completion date July 1, 2020

Study information
Verified date June 2020
Source Alexandria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Description:

Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 40
Est. completion date July 1, 2020
Est. primary completion date June 1, 2020
Accepts healthy volunteers No
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria:

- patients diagnosed with erosive OLP confirmed with a biopsy.

- patients should have symptomatic lesions

Exclusion Criteria:

- Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Matrix Metalloproteinase Inhibitors (Orochem)
topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus
• Kenacort A,
topical application of both drugs 3 times daily for 3 weeks as an active control

Locations
Country Name City State
Egypt periodontology department, Faculty of dentistry, Alexandria University Alexandria

Sponsors (1)
Lead Sponsor Collaborator
Jaylane kadry Ghonima

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary change in disease severity score Thongprasom disease severity score (5-0) change in disease severity score from baseline to 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05997173 - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed NCT02443311 - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Phase 4
Completed NCT00484250 - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Not yet recruiting NCT06428630 - Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus Early Phase 1
Completed NCT04193748 - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Phase 4
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting NCT06135805 - Impact of Fluocinonide 0,05% in Oral Lichen Planus N/A
Completed NCT04289233 - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed NCT04293718 - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed NCT00525421 - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus Phase 2
Not yet recruiting NCT04091698 - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial Phase 1
Completed NCT03386643 - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus Phase 2
Withdrawn NCT03836885 - Apremilast - Oral Lichen Planus Trial Phase 2
Completed NCT05730855 - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed NCT03257228 - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2) N/A
Recruiting NCT03026478 - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Phase 2
Completed NCT02834520 - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus N/A
Completed NCT02858297 - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus Phase 4
Completed NCT02106468 - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Phase 2